Significant Ownership of ARCH Venture Fund IX, L.P.

Signature - Title
ARCH Venture Partners IX, L.P. - its General Partner
Location
Chicago, IL
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by ARCH Venture Fund IX, L.P..

Notify me when ARCH Venture Fund IX, L.P. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of ARCH Venture Fund IX, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SANA Sana Biotechnology, Inc. Common Stock, par value $0.0001 per share 17% $163,630,594 46,093,125 Robert Nelsen 30 Sep 2025
LYEL Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share 13% $17,200,927 36,597,716 Robert Nelsen 31 Dec 2024
LYEL Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share 13% $44,807,053 2,759,072 ARCH Venture Fund IX, L.P. 30 Sep 2025
VIR Vir Biotechnology, Inc. Common Stock, $0.0001 par value 8.5% $101,645,627 13,534,704 Robert Nelsen 27 Feb 2026
BEAM Beam Therapeutics Inc. Common Stock par value $0.01 per share 4.6% $90,680,723 4,600,747 0% Robert Nelsen 31 Mar 2025
OMIC Singular Genomics Systems, Inc. Common Stock par value $0.0001 per share 0% $0 0 ARCH Venture Fund IX, L.P. 21 Feb 2025

Schedules 13D/G Reported by ARCH Venture Fund IX, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.